Summary
Boston Scientific Corporation (BSX) filed a Form 8-K on March 3, 2006, to clarify an omission in its previously filed Annual Report on Form 10-K. Specifically, the company corrected a sentence within the "Endoscopic Video Imaging" section. The corrected sentence provides updated timeline expectations for its Endovations System. This filing is important for investors as it clarifies the expected timing for key product development milestones. The company now states that it anticipates commencing first-in-man trials for the Endovations System in the second quarter of 2006, with a planned commercial launch in the U.S. in 2007. This provides more concrete guidance on the progression and market entry of this particular product line.
Key Highlights
- 1Filing corrects an inadvertent omission in the previous 10-K filing.
- 2The clarification pertains to the 'Endoscopic Video Imaging' section.
- 3Corrected sentence provides updated timeline for the Endovations System.
- 4First-in-man trials for the Endovations System are expected in Q2 2006.
- 5Commercial launch of the Endovations System in the U.S. is anticipated in 2007.
Frequently Asked Questions
The primary purpose of this 8-K filing is to correct a minor omission in Boston Scientific's recently filed Annual Report on Form 10-K. Specifically, it clarifies the expected timeline for the company's Endovations System.
Boston Scientific expects to commence first-in-man trials for the Endovations System in the second quarter of 2006.
The company anticipates a commercial launch for the Endovations System in the United States in 2007.
No, this 8-K filing is purely a technical correction to clarify product development timelines. It does not announce any new financial results, material business changes, or other significant corporate events.